Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid vs placebo in Chinese patients with primary biliary cholangitis
CTR20211958Phase 3Completed
- Sponsor
- Taizhou Fudan-Zhangjiang Pharmaceutical
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Taizhou Fudan-Zhangjiang Pharmaceutical. Started Aug 2021; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20211958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211958.